产品详情
文献和实验
相关推荐
Human Papilloma Virus (HPV)
Reproductive Health & Prenatal And Postnatal
Genetic Disease And Neonates
Respiratory Tract Infections
Devices/Instruments
Hybribio（股票代码：300639.SZ）是中国领先的核酸分子诊断产品供应商，拥有从研发、生产到销售的完整运营链。 2017年，海博生物在深交所创业板上市。
我们基于获得香港大学许可的专利技术“流通杂交”开发了体外诊断平台，并建立了两条主要的研发线——传染性病原体检测和遗传病检测。我们的产品已通过CFDA批准并获得CE-IVD许可，已广泛应用于欧洲和亚洲国家的医学和研究实验室。我们的销售和营销团队与来自不同国家的合作伙伴合作，旨在针对不同市场提供有效的战略营销计划。亚太地区、东南亚、中东、欧洲、非洲和南美洲超过 25 个国家/地区使用我们的 IVD 产品进行国家筛查、临床和研究。迄今为止，Hybribio的诊断试剂已出口到近30个国家。
Hybribio的核心专利技术获得2016年“中国专利金奖”，Hybribio的HPV诊断试剂竞争产品连续四年通过世界卫生组织外部质量评估（均100%一致）。
三作为——真实、准确、实惠——一直是我们产品的核心价值，这使我们成为中国最大的分子诊断公司之一。我们为中国1800多家医院和医疗机构提供产品和服务。 180余名科技人员常驻中国和香港，提供现场技术培训和售后技术服务支持。
凭借过去16年在分子诊断领域积累的经验和我们的研发技术，在COVID-19爆发后不久，Hybribio成功开发了两款新型冠状病毒COVID-19核酸检测试剂盒，应用分别采用荧光 RT-PCR 法和 Sanger 测序法。这两个试剂盒用于快速识别、识别疑似患者，区分流感和新型冠状病毒患者，协助医疗机构和疾控部门及时采取有效的防控措施。 3月4日，Hybribio的COVID-19实时PCR试剂盒获得欧盟CE认证。
Hybribio在中国拥有20个医学实验室，其中18个（广州、北京、重庆、济南、西安、成都、南昌、昆明、郑州、武汉、太原、上海、福州、贵阳、合肥、长沙、沉阳、向港）已获得 COVID-19 检测资格。
广东省政府已委托6家医学实验室承担COVID-19的筛查工作，Hybribio就是其中之一。预防，达标率为100%。
我们的核心企业目标之一是与合作伙伴建立长期的合作关系。我们的使命是为当地社区提供优质的服务和全面的诊断。通过将我们的实力和服务纳入我们的合作清单，我们希望这将使我们更接近我们的目标。
Hybribio (Stock code: 300639.SZ) is the leading supplier of nucleic acid molecular diagnostic products in China, with a complete operation chain, from research and development, production, to sales. In 2017, Hybribio was listed in GEM of Shenzhen Stock Exchange.
We developed our IVD platform based on patented technology - “Flow-through Hybridization”, which has been licensed by The University of Hong Kong，and established two major R&D lines - infectious pathogen detection and genetic disease detection. Our products, which have been approved by CFDA and have obtained CE-IVD licenses, have been extensively used in medical and research laboratories in European and Asian countries. Working with partners from different countries, our sales and marketing teams aim for providing an effective strategic marketing plan catered for different markets. More than 25 countries in Asia Pacific, South East Asia, Middle East, Europe, Africa, and South America use our IVD products for national screening, clinical and research purposes. So far, Hybribio’s diagnostic reagents have been exported to nearly 30 countries.
The core patented technology of Hybribio obtained "the Gold Medal of China Patent Award" in 2016, and the competitive product of Hybribio’s HPV diagnostic reagent passed the World Health Organization's External Quality Assessment for four consecutive years (all 100% consistent).
Three As – authentic, accurate, and affordable - have been the core values of our product, which have made us one of the biggest molecular diagnostic companies in China. We provide product and services to over 1800 hospitals and medical institutes in China. Over 180 scientists and technical personnel are stationed in China and Hong Kong, providing on-site technical training and after-sales technical service support.
Taking advantage of the accumulated experience in the field of molecular diagnosis and our R & D technology in the past 16 years, shortly after the outbreak of COVID-19, Hybribio has successfully developed two nucleic acid detection kits for novel coronavirus COVID-19, applying the fluorescence RT-PCR method and Sanger sequencing method respectively. The two kits were used to quickly recognize, identify suspected patients, to distinguish patients between influenza and novel coronavirus, and to assist medical institutions and disease control departments to take timely and effective prevention and control measures. On March 4th, the COVID-19 Real-Time PCR Kit of Hybribio was CE-certified by the European Union.
Hybribio has 20 Medical Laboratories all over China, and 18 of them (Guangzhou, Beijing, Chongqing, Jinan, Xi'an, Chengdu, Nanchang, Kunming, Zhengzhou, Wuhan, Taiyuan, Shanghai, Fuzhou, Guiyang, Hefei, Changsha, Shenyang, Xianggang) have obtained the qualification of COVID-19 testing.
The government of Guangdong province has entrusted 6 Medical Laboratories to undertake the screening of COVID-19 and Hybribio is one of them.The negative and positive samples detected by the Guangzhou Hybribio Medical Laboratory have been reviewed by the department of Provincial Center for Disease Control and Prevention, and the compliance rate was 100%.
One of our core corporate goals is to foster a long-lasting cooperative relationship with our partners. It is our mission to provide the local community with quality service and comprehensive diagnosis. By incorporating our strength and service to our list of collaborations, we hope it will bring us one step closer to our goal.
Reproductive Health & Prenatal And Postnatal
Genetic Disease And Neonates
Respiratory Tract Infections
Devices/Instruments
Hybribio（股票代码：300639.SZ）是中国领先的核酸分子诊断产品供应商，拥有从研发、生产到销售的完整运营链。 2017年，海博生物在深交所创业板上市。
我们基于获得香港大学许可的专利技术“流通杂交”开发了体外诊断平台，并建立了两条主要的研发线——传染性病原体检测和遗传病检测。我们的产品已通过CFDA批准并获得CE-IVD许可，已广泛应用于欧洲和亚洲国家的医学和研究实验室。我们的销售和营销团队与来自不同国家的合作伙伴合作，旨在针对不同市场提供有效的战略营销计划。亚太地区、东南亚、中东、欧洲、非洲和南美洲超过 25 个国家/地区使用我们的 IVD 产品进行国家筛查、临床和研究。迄今为止，Hybribio的诊断试剂已出口到近30个国家。
Hybribio的核心专利技术获得2016年“中国专利金奖”，Hybribio的HPV诊断试剂竞争产品连续四年通过世界卫生组织外部质量评估（均100%一致）。
三作为——真实、准确、实惠——一直是我们产品的核心价值，这使我们成为中国最大的分子诊断公司之一。我们为中国1800多家医院和医疗机构提供产品和服务。 180余名科技人员常驻中国和香港，提供现场技术培训和售后技术服务支持。
凭借过去16年在分子诊断领域积累的经验和我们的研发技术，在COVID-19爆发后不久，Hybribio成功开发了两款新型冠状病毒COVID-19核酸检测试剂盒，应用分别采用荧光 RT-PCR 法和 Sanger 测序法。这两个试剂盒用于快速识别、识别疑似患者，区分流感和新型冠状病毒患者，协助医疗机构和疾控部门及时采取有效的防控措施。 3月4日，Hybribio的COVID-19实时PCR试剂盒获得欧盟CE认证。
Hybribio在中国拥有20个医学实验室，其中18个（广州、北京、重庆、济南、西安、成都、南昌、昆明、郑州、武汉、太原、上海、福州、贵阳、合肥、长沙、沉阳、向港）已获得 COVID-19 检测资格。
广东省政府已委托6家医学实验室承担COVID-19的筛查工作，Hybribio就是其中之一。预防，达标率为100%。
我们的核心企业目标之一是与合作伙伴建立长期的合作关系。我们的使命是为当地社区提供优质的服务和全面的诊断。通过将我们的实力和服务纳入我们的合作清单，我们希望这将使我们更接近我们的目标。
Hybribio (Stock code: 300639.SZ) is the leading supplier of nucleic acid molecular diagnostic products in China, with a complete operation chain, from research and development, production, to sales. In 2017, Hybribio was listed in GEM of Shenzhen Stock Exchange.
We developed our IVD platform based on patented technology - “Flow-through Hybridization”, which has been licensed by The University of Hong Kong，and established two major R&D lines - infectious pathogen detection and genetic disease detection. Our products, which have been approved by CFDA and have obtained CE-IVD licenses, have been extensively used in medical and research laboratories in European and Asian countries. Working with partners from different countries, our sales and marketing teams aim for providing an effective strategic marketing plan catered for different markets. More than 25 countries in Asia Pacific, South East Asia, Middle East, Europe, Africa, and South America use our IVD products for national screening, clinical and research purposes. So far, Hybribio’s diagnostic reagents have been exported to nearly 30 countries.
The core patented technology of Hybribio obtained "the Gold Medal of China Patent Award" in 2016, and the competitive product of Hybribio’s HPV diagnostic reagent passed the World Health Organization's External Quality Assessment for four consecutive years (all 100% consistent).
Three As – authentic, accurate, and affordable - have been the core values of our product, which have made us one of the biggest molecular diagnostic companies in China. We provide product and services to over 1800 hospitals and medical institutes in China. Over 180 scientists and technical personnel are stationed in China and Hong Kong, providing on-site technical training and after-sales technical service support.
Taking advantage of the accumulated experience in the field of molecular diagnosis and our R & D technology in the past 16 years, shortly after the outbreak of COVID-19, Hybribio has successfully developed two nucleic acid detection kits for novel coronavirus COVID-19, applying the fluorescence RT-PCR method and Sanger sequencing method respectively. The two kits were used to quickly recognize, identify suspected patients, to distinguish patients between influenza and novel coronavirus, and to assist medical institutions and disease control departments to take timely and effective prevention and control measures. On March 4th, the COVID-19 Real-Time PCR Kit of Hybribio was CE-certified by the European Union.
Hybribio has 20 Medical Laboratories all over China, and 18 of them (Guangzhou, Beijing, Chongqing, Jinan, Xi'an, Chengdu, Nanchang, Kunming, Zhengzhou, Wuhan, Taiyuan, Shanghai, Fuzhou, Guiyang, Hefei, Changsha, Shenyang, Xianggang) have obtained the qualification of COVID-19 testing.
The government of Guangdong province has entrusted 6 Medical Laboratories to undertake the screening of COVID-19 and Hybribio is one of them.The negative and positive samples detected by the Guangzhou Hybribio Medical Laboratory have been reviewed by the department of Provincial Center for Disease Control and Prevention, and the compliance rate was 100%.
One of our core corporate goals is to foster a long-lasting cooperative relationship with our partners. It is our mission to provide the local community with quality service and comprehensive diagnosis. By incorporating our strength and service to our list of collaborations, we hope it will bring us one step closer to our goal.
北京美科美生物技术开发有限公司
代理商实名认证
钻石会员
入驻年限：11年
